|
Post by suebeeee1 on Jan 6, 2016 11:03:17 GMT -5
I am averaging down some more too. Al had said in the past that the price for Afrezza would be comparable to insulin pens, so they should have some runway to lower the price, which should help with insurance coverage. I also believe there is some low hanging fruit for use off-shore, and that there will be some good news on the Technosphere front soon. Maybe I am just stubborn and naive, but I CANNOT believe that a better performing insulin that does not require injection cannot ultimately be successful in the marketplace. With dodgy insurance coverage and doctor reluctance, the best drug in the world is doomed to fail, at least in the US. I wonder if the US will now take a back seat to target a few other willing countries for Mannkind to let Afrezza stretch its legs. I am not sure we will get a clear picture next week at JPM of what strategy Mannkind will take. They had better come up with a strategy as fast as lightning. In fact, they better have been putting together a strategy for the past 6 months. If not, we are doomed. At the very least, management read the tea leaves, but without formulating a plan, they would have been even more incomptetent than they have already appeared to be. The conference will tell us everything we need to know. If the new CEO comes up with a coherent strategy, I know we will be ok.
|
|
|
Post by mnkdnewb on Jan 6, 2016 11:15:01 GMT -5
Talk about averaging down.... Good for you Sue! After digesting this a little bit I am actually glad they did it so soon. They could have kept sand bagging for a while & that would have probably killed MNKD & us. I'm glad they did it now, too. I wonder if sny knew we were going to part ways with them which scared them enough to do what they could to hurt Mnkd by dropping them first and kicking us by saying "there isn't a market for it, we tried hard, going to take a lot more money for a long time, etc" hoping it would deter another company or hurt Mnkd enough so they could buy us up cheap...
|
|
|
Post by dictatorsaurus on Jan 6, 2016 11:25:53 GMT -5
...or hurt Mnkd enough so they could buy us up cheap... Sanofi is not going to buy Afrezza or Mannkind. They never intended to. It's as clear as daylight they intended to kill the drug and wipe us off the face of the earth. They never promoted it, they dumped us and now they are trashing us in the media claiming there's no market for the drug. Sanofi stinks and I never trusted them. Looking forward to a better future through a better partner or a buyout.
|
|
|
Post by mindovermatter on Jan 6, 2016 11:28:13 GMT -5
With dodgy insurance coverage and doctor reluctance, the best drug in the world is doomed to fail, at least in the US. I wonder if the US will now take a back seat to target a few other willing countries for Mannkind to let Afrezza stretch its legs. I am not sure we will get a clear picture next week at JPM of what strategy Mannkind will take. They had better come up with a strategy as fast as lightning. In fact, they better have been putting together a strategy for the past 6 months. If not, we are doomed. At the very least, management read the tea leaves, but without formulating a plan, they would have been even more incomptetent than they have already appeared to be. The conference will tell us everything we need to know. If the new CEO comes up with a coherent strategy, I know we will be ok. Again, don't be so sure we will hear a lot from the conference. I think we will hear more of, "we are working on......and we'll have more information to give out in the near future."
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 11:31:21 GMT -5
They had better come up with a strategy as fast as lightning. In fact, they better have been putting together a strategy for the past 6 months. If not, we are doomed. At the very least, management read the tea leaves, but without formulating a plan, they would have been even more incomptetent than they have already appeared to be. The conference will tell us everything we need to know. If the new CEO comes up with a coherent strategy, I know we will be ok. Again, don't be so sure we will hear a lot from the conference. I think we will hear more of, "we are working on......and we'll have more information to give out in the near future." I will be the first one to say I think they are done but they will be very forth coming at that conference. They have no choice now.
|
|
|
Post by mnkdnewb on Jan 6, 2016 11:39:29 GMT -5
...or hurt Mnkd enough so they could buy us up cheap... Sanofi is not going to buy Afrezza or Mannkind. They never intended to. It's as clear as daylight they intended to kill the drug and wipe us off the face of the earth. They never promoted it, they dumped us and now they are trashing us in the media claiming there's no market for the drug. Sanofi stinks and I never trusted them. Looking forward to a better future through a better partner or a buyout. You are correct. I should have said "buy us up cheap even if it is just to bury afrezza"
|
|
|
Post by kc on Jan 6, 2016 11:41:18 GMT -5
Again, don't be so sure we will hear a lot from the conference. I think we will hear more of, "we are working on......and we'll have more information to give out in the near future." I will be the first one to say I think they are done but they will be very forth coming at that conference. They have no choice now. You have to have something to say that will drive the market and I agree with you that they probably don't have anything new to bring up. The company needs to be sold. Perhaps they will state they are looking for a new partner for Afrezza but that does not deal with the real issue. The company without more dilution and crippling debt is cooked without a new owner. Only Al can make that sale happen since he controls 45% or more of the stock.
|
|
|
Post by mindovermatter on Jan 6, 2016 11:47:58 GMT -5
I will be the first one to say I think they are done but they will be very forth coming at that conference. They have no choice now. You have to have something to say that will drive the market and I agree with you that they probably don't have anything new to bring up. The company needs to be sold. Perhaps they will state they are looking for a new partner for Afrezza but that does not deal with the real issue. The company without more dilution and crippling debt is cooked without a new owner. Only Al can make that sale happen since he controls 45% or more of the stock. If Mannkind gives specifics and lays out their strategy then this would tell us they have been working on this for awhile thus proving they knew the partnership was heading towards dissolution months ago.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 12:06:10 GMT -5
You have to have something to say that will drive the market and I agree with you that they probably don't have anything new to bring up. The company needs to be sold. Perhaps they will state they are looking for a new partner for Afrezza but that does not deal with the real issue. The company without more dilution and crippling debt is cooked without a new owner. Only Al can make that sale happen since he controls 45% or more of the stock. If Mannkind gives specifics and lays out their strategy then this would tell us they have been working on this for awhile thus proving they knew the partnership was heading towards dissolution months ago. cant get they something up in a week with the new ceo ( even if they have been working for a while ).. if you look at it, there are a few finite variables only if your removing pricing issues
|
|
|
Post by iclaudius on Jan 6, 2016 12:32:23 GMT -5
Some months ago, I postulated a TEVA partnership on the Yahoo board, over a series of several posts under proulxra59. Then they bought Allergan's generic drug business, including $20 B cash, which limits their ability with respect to a buyout, but not a partnership. I highlighted the similarities between the drug specialization within TEVA's Global Branded Products group and MNKDS stated TECHNOSPHERE product line candidates and they match up extremely well. There was also that job posting at MNKD for a VP of a partnership, which lasted about 24 hours on their website before it was taken down. It specifically referenced being a member of the GLOBAL branded Products group. That is most certainly TEVA. There are machinations taking place behind the scenes to which we're not privy and I highly suspect that there was a buyout offer which SNY was offered to match and chose not to do so. I believe that SNY was interested in the whole enchilada and signed the partnership because they could not come to terms. I would theorize that the San Diego meeting was a last ditch due diligence effort to determine if they should increase their offer. They ultimately realized that they would never be able to come to terms and elected to bail as opposed to accepting the risk of not being able to profit from the deal given what Al Mann was asking. I think that Sanofi and Mannkind played a game of poker and Al might have wanted too much and Sanofi decided to not blink. So the partnership was terminated. I do hope that Mannkind has a plan with a sale to a company like Teva or Perigo who has distribution, sales network and the ability to monetize Afrezza into a winning product that helps the diabetic live a better life.
You point is right on target about Teva's Global Branded products group. They have a lot of R & D into inhalable so Technosphere fits right into their program. Additionally they have some very smart Israeli Bio scientist's who can run with some of the patents MannKind has and commercialize some new products. It won't happen as a partnership it would have to be a sale. I hope that Mann can live with that to save the company. Hopefully he will get the deal done while MannKind is solvent.
I don't believe there was a "poker game." The previous Sanofi CEO had a grand marketing plan that revolved around "listening to the patient." He felt afrezza would fit into that plan, hence the deal. Sanofi's BOD didn't agree with those plans and fired him. The person hired to replace him happened to have been an important member of the team that directed the failed exubera launch. Whether that was a reason for hiring him is unknown. In any case, new team means new strategy. If afrezza didn't fit in with the new strategy, then the decision is made that no further money or effort will be invested in marketing it -- simple as that. It seems like MNKD management should have understood the risks of the new CEO and taken appropriate cautionary measures -- e.g. preserving cash, lining up financing, etc.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 12:37:58 GMT -5
I think that Sanofi and Mannkind played a game of poker and Al might have wanted too much and Sanofi decided to not blink. So the partnership was terminated. I do hope that Mannkind has a plan with a sale to a company like Teva or Perigo who has distribution, sales network and the ability to monetize Afrezza into a winning product that helps the diabetic live a better life.
You point is right on target about Teva's Global Branded products group. They have a lot of R & D into inhalable so Technosphere fits right into their program. Additionally they have some very smart Israeli Bio scientist's who can run with some of the patents MannKind has and commercialize some new products. It won't happen as a partnership it would have to be a sale. I hope that Mann can live with that to save the company. Hopefully he will get the deal done while MannKind is solvent.
I don't believe there was a "poker game." The previous Sanofi CEO had a grand marketing plan that revolved around "listening to the patient." He felt afrezza would fit into that plan, hence the deal. Sanofi's BOD didn't agree with those plans and fired him. The person hired to replace him happened to have been an important member of the team that directed the failed exubera launch. Whether that was a reason for hiring him is unknown. In any case, new team means new strategy. If afrezza didn't fit in with the new strategy, then the decision is made that no further money or effort will be invested in marketing it -- simple as that. It seems like MNKD management should have understood the risks of the new CEO and taken appropriate cautionary measures -- e.g. preserving cash, lining up financing, etc. Hind sight is 20-20 but MNKD should fire their lawyers for not having an out clause in their partnership if there was a restructuring in management. This again shows how out of their league this whole process has been.
|
|
|
Post by cjc04 on Jan 6, 2016 12:58:24 GMT -5
I think that Sanofi and Mannkind played a game of poker and Al might have wanted too much and Sanofi decided to not blink. So the partnership was terminated. I do hope that Mannkind has a plan with a sale to a company like Teva or Perigo who has distribution, sales network and the ability to monetize Afrezza into a winning product that helps the diabetic live a better life.
You point is right on target about Teva's Global Branded products group. They have a lot of R & D into inhalable so Technosphere fits right into their program. Additionally they have some very smart Israeli Bio scientist's who can run with some of the patents MannKind has and commercialize some new products. It won't happen as a partnership it would have to be a sale. I hope that Mann can live with that to save the company. Hopefully he will get the deal done while MannKind is solvent.
I don't believe there was a "poker game." The previous Sanofi CEO had a grand marketing plan that revolved around "listening to the patient." He felt afrezza would fit into that plan, hence the deal. Sanofi's BOD didn't agree with those plans and fired him. The person hired to replace him happened to have been an important member of the team that directed the failed exubera launch. Whether that was a reason for hiring him is unknown. In any case, new team means new strategy. If afrezza didn't fit in with the new strategy, then the decision is made that no further money or effort will be invested in marketing it -- simple as that. It seems like MNKD management should have understood the risks of the new CEO and taken appropriate cautionary measures -- e.g. preserving cash, lining up financing, etc. Well said!!! I remember feeling and reading the concern with SNY's CEO change when it happen, so it MUST have put MNKD on alert from day 1 and through out the last year probably becoming clear mid year with SNY's weak effort. So I believe MNKD has to be prepared for this, or at least not completely shocked. But He was fired in October of 2014, Plenty of time to scrap the deal before the 2015 launch...... Then again, I still think that Mann whole hearted believed that Afrezza would take off on its own via an underground wave of word of mouth from diabetics, so he probably felt like he already won by getting the deal inked in the first place.
|
|
|
Post by slugworth008 on Jan 6, 2016 13:13:15 GMT -5
I invested in SNY after they partnered with MNKD. Today I sold all my shares, even at a loss. That will be tens of thousands more I have available to invest in MNKD over the next few days..... Nice work Suebeeee1. SNY will see their PPS in the 30's soon. IMO If I owned any SNY shares I would have sold them based on principle alone. Screw'm
|
|
|
Post by kc on Jan 26, 2016 19:56:34 GMT -5
Seems that big Pharma really has a monopoly on product and pricing. It would be great to underprice them and deliver a better product. We go screwed by Sanofi. They knew that the could kill Afrezza by over pricing the product in the market. MannKind needs to find a way to get back into the market with a good company and a distribution network and sell it as cheaply as the can. perhaps even pricing if the can close to generic pens. Put the pressure on the big boys. I hope they figure how to get engaged with a company that understands that market. Like Teva or Perigo. There are others in that space. Mannkind can't go it alone. They have to be part of something bigger to survive at this point. The Company needs to be sold. Sadly if it does not get sold than we all lose our investment. So hopefully smarter people are working hard to get a Teva interested. It would be great to have a named brand product Afrezza priced close to what a Generic pen sells for to the consumer. It won't happen unless they take the lumps and make a deal with somebody quickly. Read more: mnkd.proboards.com/thread/4737/pricing-point?page=2#ixzz3wTdy7RwoWould like to see it be Teva. That would be the best thing to have a strong company like them go Head to head with Sanofi. Branded Teva Afrezza with generic Lantus made by Teva. Let's crush Sanofi.
|
|
|
Post by bradleysbest on Jan 26, 2016 21:34:45 GMT -5
Love the last 2 posts! Make it happen Al.
|
|